Hiv Specific Articles & Analysis
2 news found
The FDA’s guidance was received in written response to Biotron’s pre-IND briefing package and request in March 2022, which included an overview of preclinical and (HIV) clinical development, and specific questions relating to regulatory requirements for progression to filing an investigational new drug (‘IND’) application for the COVID-19 ...
The design of these multi-specifics is amenable to gene-based delivery by mRNA or DNA vectors. ...